Combined betaseron R (recombinant human interferon beta) and radiation for inoperable non-small cell lung cancer
- Univ. of Rochester Cancer Center, Rochester, NY (United States)
Based on in vitro evidence of radiosensitization by Betaseron{reg_sign} ({beta}-IFN), a Phase I/II study was undertaken to determine toxicity and response using combined radiation (RT) and {beta}-IFN in patients with unresectable Stage III and nonsmall cell lung cancer. Varying doses of {beta}-IFN(10 to 90 {times} 10{sup 6} IU) were administered IV immediately preceding RT on the first three days of weeks 1, 3, and 5. The RT dose was 1.8 Gy/day, 5 days/week for a total of 54 or 59.4 Gy. Thirty-nine patients were entered, 32 of whom were evaluable. The median follow-up at time of analysis was 60 months. Responses were based on CT scan. The response rate for the total group was 81% with 44% achieving complete response. Seventy-eight percent of patients with complete response survived a minimum of 21 months. Twenty-six patients had Stage III A/B disease with a median tumor size of 6.5 cm and median survival was 19.7 months. The 5-year actuarial survival for this group was 31%, with a plateau persisting after 3 years. There were no treatment related deaths nor any event of life threatening toxicity. Of eight patients surviving 3-5 years, no long-term toxicity has been observed. Karofsky indices were 90-100 and respiratory symptoms were minimal. {beta}-IFN is well-tolerated. Response and survival rates are sufficiently encouraging to warrant further investigation in a randomized trial which has been accepted as an RTOG study awaiting drug availability. 31 refs., 5 figs., 1 tab.
- Sponsoring Organization:
- USDOE
- OSTI ID:
- 54867
- Journal Information:
- International Journal of Radiation Oncology, Biology and Physics, Vol. 27, Issue 3; Other Information: PBD: 20 Oct 1993
- Country of Publication:
- United States
- Language:
- English
Similar Records
Phase 2 Randomized Controlled Trial of Radiation Therapy Plus Concurrent Interferon-Alpha and Retinoic Acid Versus Cisplatin for Stage III Cervical Carcinoma
A Phase II Study of Synchronous Three-Dimensional Conformal Boost to the Gross Tumor Volume for Patients With Unresectable Stage III Non-Small-Cell Lung Cancer: Results of Korean Radiation Oncology Group 0301 Study